Verd et lodd?
ifecare tests groundbreaking technology to analyze human data and strengthens core team

29.11.2019, Oslo – Today Lifecare AS, a Norwegian life-science company, announced that they are getting ready to test their sensing technology on human data. This is a significant advancement in the development of the solutions to address the diabetes epidemic.

Lifecare AS researches and develops miniature sensors for convenient glucose monitoring for a global market. The testing is the next phase of the development of the technology and it enables the company to generate human data, earlier than expected, with the groundbreaking technology.

“This is another step towards miniaturizing the Sencell Glucose Sensor,” says Dr Andreas Pfûtzner, CSO, Lifecare. “The sensor has now been developed to a point where it is already smaller than the initial targeted size. This allows the sensing element to be put into a hypodermic needle. A needle sensor will also represent an additional product opportunity. We are proud that we are now able to start the testing after initiating the regulatory process for the first clinical study.”

Lifecare is developing an implantable continuous glucose sensor based on its proprietary osmotic pressure cell technology. The news about the upcoming tests comes after Lifecare announced in April 2019 that its nanosensor technology has been shown in laboratory experiments to accurately measure pressure changes derived from substantially smaller osmotic pressure chambers than previously available.

Strengthening core team

In this process, Lifecare has increased its team with two talented new colleagues; Dr. Konstantin Kloppstech, a world leading expert in sensor-technology and former Head of Technology at cantiMED, and Dr. Frank Flacke, the former Medical Director Devices in the global CVD division of Sanofi. Both have now joined Lifecare’s core team and are together spearheading the sensor development. Kloppstech and Flacke have purchased shares in Lifecare from the Chairman of the Board, Christian Saure – please see separate press release.